Khreish and others hypothesized that among the patients, who showed no response to 177Lu-PSMA ligand alone, a tandem treatment, consisting of low-activity 225Ac-PSMA ligand and high-activity beta emitter ligand, could increase the effectiveness while decreasing the xerostomia severity. This evidence concerns the gene FOLH1 and xerostomia.